Cargando…
The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
Antiphospholipid syndrome (APS) is an autoimmune disease mainly characterised by vascular thrombosis and pregnancy morbidity. APS has broad spectrum of clinical manifestations. The digestive system involvement of antiphospholipid syndrome is a critical but under-recognised condition. Digestive syste...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381908/ https://www.ncbi.nlm.nih.gov/pubmed/34409894 http://dx.doi.org/10.1080/07853890.2021.1962964 |
_version_ | 1783741452073828352 |
---|---|
author | Zhang, Jin Li, Cheng Han, Xiaorong Chen, Zhongbo Adhikari, Binay Kumar Wang, Yinghui Wang, Yonggang Sun, Jian |
author_facet | Zhang, Jin Li, Cheng Han, Xiaorong Chen, Zhongbo Adhikari, Binay Kumar Wang, Yinghui Wang, Yonggang Sun, Jian |
author_sort | Zhang, Jin |
collection | PubMed |
description | Antiphospholipid syndrome (APS) is an autoimmune disease mainly characterised by vascular thrombosis and pregnancy morbidity. APS has broad spectrum of clinical manifestations. The digestive system involvement of antiphospholipid syndrome is a critical but under-recognised condition. Digestive system involvement may be the result of direct (autoimmune-mediated) or indirect (thrombotic) mechanisms. Liver is the most commonly involved organ, followed by intestines, oesophagus, stomach, pancreas and spleen. This review describes possible digestive system manifestations in APS patients, and illustrates the epidemiology and possible pathophysiology of APS. The role of different treatment strategies in the management of digestive system manifestations of APS were also discussed. KEY MESSAGES: Antiphospholipid syndrome is a multi-organ, multi-system disease and its clinical manifestation spectrum is gradually expanding. Since the first diagnosis of APS, the clinical manifestations of digestive system have been reported successively. This narrative review describes the major digestive system manifestations of APS and illustrates the epidemiology, pathophysiology and the role of therapeutic strategies of these patients. |
format | Online Article Text |
id | pubmed-8381908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-83819082021-08-24 The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies Zhang, Jin Li, Cheng Han, Xiaorong Chen, Zhongbo Adhikari, Binay Kumar Wang, Yinghui Wang, Yonggang Sun, Jian Ann Med Rheumatology Antiphospholipid syndrome (APS) is an autoimmune disease mainly characterised by vascular thrombosis and pregnancy morbidity. APS has broad spectrum of clinical manifestations. The digestive system involvement of antiphospholipid syndrome is a critical but under-recognised condition. Digestive system involvement may be the result of direct (autoimmune-mediated) or indirect (thrombotic) mechanisms. Liver is the most commonly involved organ, followed by intestines, oesophagus, stomach, pancreas and spleen. This review describes possible digestive system manifestations in APS patients, and illustrates the epidemiology and possible pathophysiology of APS. The role of different treatment strategies in the management of digestive system manifestations of APS were also discussed. KEY MESSAGES: Antiphospholipid syndrome is a multi-organ, multi-system disease and its clinical manifestation spectrum is gradually expanding. Since the first diagnosis of APS, the clinical manifestations of digestive system have been reported successively. This narrative review describes the major digestive system manifestations of APS and illustrates the epidemiology, pathophysiology and the role of therapeutic strategies of these patients. Taylor & Francis 2021-08-19 /pmc/articles/PMC8381908/ /pubmed/34409894 http://dx.doi.org/10.1080/07853890.2021.1962964 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Rheumatology Zhang, Jin Li, Cheng Han, Xiaorong Chen, Zhongbo Adhikari, Binay Kumar Wang, Yinghui Wang, Yonggang Sun, Jian The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
title | The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
title_full | The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
title_fullStr | The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
title_full_unstemmed | The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
title_short | The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
title_sort | digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies |
topic | Rheumatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381908/ https://www.ncbi.nlm.nih.gov/pubmed/34409894 http://dx.doi.org/10.1080/07853890.2021.1962964 |
work_keys_str_mv | AT zhangjin thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT licheng thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT hanxiaorong thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT chenzhongbo thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT adhikaribinaykumar thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT wangyinghui thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT wangyonggang thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT sunjian thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT zhangjin digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT licheng digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT hanxiaorong digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT chenzhongbo digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT adhikaribinaykumar digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT wangyinghui digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT wangyonggang digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies AT sunjian digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies |